Geron (NASDAQ:GERN) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Geron (NASDAQ:GERN) in a research note released on Thursday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $4.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. ValuEngine raised shares of Geron from a hold rating to a buy rating in a report on Saturday, August 10th. B. Riley lifted their price target on shares of Geron from $3.25 to $4.50 and gave the company a buy rating in a report on Friday, June 28th. Finally, BidaskClub lowered shares of Geron from a hold rating to a sell rating in a report on Thursday, June 13th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $3.46.

Shares of Geron stock opened at $1.41 on Thursday. The firm has a market capitalization of $261.91 million, a PE ratio of -8.81 and a beta of 2.59. The firm’s 50 day moving average is $1.29 and its 200 day moving average is $1.51. Geron has a 1 year low of $0.95 and a 1 year high of $6.99.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. Geron had a negative net margin of 5,328.80% and a negative return on equity of 22.33%. As a group, equities research analysts predict that Geron will post -0.44 EPS for the current year.

A number of large investors have recently bought and sold shares of GERN. Jane Street Group LLC purchased a new position in Geron during the second quarter valued at $71,000. Vanguard Group Inc. lifted its position in Geron by 1.5% during the second quarter. Vanguard Group Inc. now owns 9,644,900 shares of the biopharmaceutical company’s stock valued at $13,599,000 after buying an additional 141,384 shares during the period. Tower Research Capital LLC TRC lifted its position in Geron by 482.4% during the second quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 24,684 shares during the period. Virtus ETF Advisers LLC purchased a new position in Geron during the second quarter valued at $252,000. Finally, Bank of New York Mellon Corp lifted its position in Geron by 11.0% during the second quarter. Bank of New York Mellon Corp now owns 805,331 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 79,827 shares during the period. Institutional investors and hedge funds own 31.06% of the company’s stock.

Geron Company Profile

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Further Reading: Rule of 72

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.